News

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
StockStory.org on MSN23h
Why Moderna (MRNA) Stock Is Up Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food and Drug ...
Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...